Xilio Therapeutics Announces Closing of $50.0 Million Public Offering
Summary
Xilio Therapeutics closed a public offering that brought in about $50 million in gross proceeds. The company also structured additional warrants that could add up to $100 million more if exercised by 2026. Xilio plans to use the proceeds to advance its product pipeline and support working capital and general corporate needs. The financing was co-led by new investors Coastlands Capital and Frazier Life Sciences, with participation from several existing and new institutional investors.
Funding
Amount
$50.0M
Total raised
Date
June 5, 2025
Announcement date
Investors
Logos Capital, Leerink Swann & Company, Samsara BioCapital, Gild
Lead investors
Company
xiliotx.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected